Tocagen Inc (TOCA) Short Interest Update

Tocagen Inc (NASDAQ:TOCA) saw a significant growth in short interest in the month of December. As of December 29th, there was short interest totalling 1,208,548 shares, a growth of 38.7% from the December 15th total of 871,611 shares. Currently, 7.1% of the shares of the company are sold short. Based on an average daily volume of 177,614 shares, the short-interest ratio is currently 6.8 days.

Several institutional investors have recently modified their holdings of the business. New York State Common Retirement Fund acquired a new position in shares of Tocagen in the second quarter worth about $108,000. Schwab Charles Investment Management Inc. acquired a new position in shares of Tocagen in the second quarter worth about $165,000. BBR Partners LLC acquired a new position in shares of Tocagen in the third quarter worth about $181,000. California State Teachers Retirement System acquired a new position in shares of Tocagen in the second quarter worth about $179,000. Finally, Teachers Advisors LLC acquired a new position in shares of Tocagen in the second quarter worth about $181,000. Institutional investors and hedge funds own 36.22% of the company’s stock.

Separately, Zacks Investment Research downgraded shares of Tocagen from a “hold” rating to a “sell” rating in a research report on Wednesday, September 27th.

Tocagen (NASDAQ TOCA) opened at $12.83 on Friday. The stock has a market cap of $254.16 and a price-to-earnings ratio of -6.42. Tocagen has a 1 year low of $8.60 and a 1 year high of $17.95. The company has a current ratio of 6.03, a quick ratio of 6.03 and a debt-to-equity ratio of 0.07.

Tocagen (NASDAQ:TOCA) last issued its quarterly earnings data on Wednesday, November 8th. The company reported ($0.50) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.02). The business had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.01 million. equities analysts anticipate that Tocagen will post -2.66 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This news story was posted by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this news story on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this news story can be viewed at https://stocknewstimes.com/2018/01/19/tocagen-inc-toca-short-interest-update.html.

Tocagen Company Profile

Tocagen Inc (Tocagen) is a clinical-stage, cancer-selective gene therapy company. The Company is focused on developing product candidates designed to activate a patient’s immune system against their own cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to selectively deliver therapeutic genes into the deoxyribonucleic acid (DNA) of cancer cells.

Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply